Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Trodelvy improved PFS by 34% in heavily pre-treated patients

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 11, 2023 4:58pm

190 Views

Post# 35490776

RE:RE:RE:RE:RE:RE:RE:RE:Trodelvy improved PFS by 34% in heavily pre-treated patients

Moreover, Trodelvey is an ADC.

While I know nothing about ADC's, my guess is that it may not be relevant for other indications than triple neg mBC.

On the other hand, pela shows well in an array of indications, and is a top performer (so far) on panc.

So while Immunometics had a variety of drugs (ADCs, I guess) when it was aquired for $11 bil, we have only one, but it works in a wide array of indications.

So there is a lot of value in ONCY, from that comparable.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China